Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

1.4%

1 terminated/withdrawn out of 72 trials

Success Rate

90.9%

+4.4% vs industry average

Late-Stage Pipeline

40%

29 trials in Phase 3/4

Results Transparency

0%

0 of 10 completed trials have results

Key Signals

22 recruiting

Enrollment Performance

Analytics

Phase 3
29(48.3%)
Phase 2
23(38.3%)
N/A
5(8.3%)
Early Phase 1
2(3.3%)
Phase 1
1(1.7%)
60Total
Phase 3(29)
Phase 2(23)
N/A(5)
Early Phase 1(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (72)

Showing 20 of 72 trials
NCT05242692Early Phase 1Completed

The Effects of Subanesthetic S-ketamine on Postoperative Delirium and Cognitive Function in the Elderly Undergoing Non-cardiac Thoracic Surgery

Role: lead

NCT04944914Phase 3Recruiting

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

Role: collaborator

NCT06140992Recruiting

PaCIFiC-CUP Classifies Cancer of Unknown Primary

Role: collaborator

NCT05871099Phase 3Recruiting

Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not

Role: collaborator

NCT07311772Phase 3Recruiting

Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid

Role: collaborator

NCT07286253Phase 2Recruiting

QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial

Role: lead

NCT07286240Phase 2Recruiting

QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer

Role: lead

NCT07188584Phase 3Recruiting

Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

Role: collaborator

NCT03387774Phase 3Completed

Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients

Role: collaborator

NCT06244368Phase 2Recruiting

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Role: collaborator

NCT04517214Phase 2Active Not Recruiting

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Role: collaborator

NCT06831357Recruiting

Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI

Role: collaborator

NCT06829147Recruiting

A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)

Role: collaborator

NCT03840421Phase 3Active Not Recruiting

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT06458673Not Yet Recruiting

A Prospective, Non-interventional Cohort Study of Subsolid Pulmonary Nodules

Role: collaborator

NCT06594172Phase 2Not Yet Recruiting

Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy

Role: lead

NCT06570538Early Phase 1Not Yet Recruiting

Analgesic Efficacy of an Opioid-free Postoperative Pain Management Strategy Versus a Conventional Opioid-based Strategy Following Video-assisted Thoracoscopic Lobectomy

Role: lead

NCT05892354Not ApplicableRecruiting

Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy

Role: collaborator

NCT06531850Unknown

Prospective Study of Serum Marker LncRNA RP5-977B1 in Pulmonary Nodules

Role: lead

NCT04922658Phase 2Recruiting

Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

Role: lead